Study In Patients With Kidney Cancer Treated With Sutent

Pfizer logo

Pfizer

Status

Completed

Conditions

Advanced or Metastatic Renal Cell Carcinoma
Renal Cancer

Treatments

Drug: Sutent

Study type

Observational

Funder types

Industry

Identifiers

NCT00873210
A6181185

Details and patient eligibility

About

Objective of this study is to increase knowledge about safety, tolerability, quality of life and efficacy under conditions of routine use of sunitinib.

Full description

Consecutive patients with advanced or metastatic renal cell carcinoma, that are indicated for 1st or 2nd line anticancer therapy

Enrollment

121 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Consecutive patients with advanced or metastatic renal cell carcinoma, that are indicated for 1st or 2nd line anticancer therapy

Exclusion criteria

  • Hypersensitivity to sunitinib malate or to any of the excipients
  • Any other contraindication to the use of sunitinib malate (based on decision of the treating physician).

Trial design

121 participants in 1 patient group

Patients treated with Sutent
Description:
125 consecutive patients in outpatient care with advanced or metastatic renal cell carcinoma, that are indicated for 1st or 2nd line anticancer therapy
Treatment:
Drug: Sutent

Trial contacts and locations

14

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems